Fatty liver and MASLD: what to do after an ultrasound finding
A finding of fatty liver requires assessment and monitoring, but does not by itself mean there is inflammation or advanced scarring in the liver. Developments in drug treatments also highlight the distinction: a U.S. approval from August 2025 was intended for a defined population with MASH and fibrosis, not everyone with a similar ultrasound result.
Adi Way Editorial TeamPublished:
Fatty liver can appear in a test report without any pain having prompted the test. The next question is not simply how to remove fat from your diet. You need to understand what lies behind the finding, whether metabolic risk factors are present, and whether tests to assess liver scarring are needed.
Ultrasound identifies fat but does not grade the entire disease
Fat accumulation in the liver is called steatosis. Standard ultrasound may identify it, but cannot determine on its own whether inflammation and liver cell injury are present, and does not reliably grade fibrosis, meaning scar tissue.
According to the joint 2024 guidelines of the European liver, diabetes, and obesity associations, an incidental finding like this warrants investigation of the cause and assessment of advanced fibrosis risk. It does not mean everyone will need a biopsy or develop cirrhosis. The goal is to identify who needs closer monitoring without turning every finding into an emergency.
Why the name changed to MASLD
In June 2023, new terminology was announced through a multisociety consensus led by AASLD, EASL and ALEH. The term MASLD replaced NAFLD, the name used for fatty liver not associated with significant alcohol consumption. In Hebrew, it can be described as fatty liver disease associated with metabolic dysfunction.
This is not simply an update to an abbreviation. The definition combines liver fat and at least one cardiometabolic risk factor, such as an abnormal blood sugar level, alongside assessment of alcohol consumption and other causes. Insulin resistance, type 2 diabetes, and abdominal obesity are particularly relevant, but the disease can also occur at a normal weight.
MASH describes a condition in which inflammation and liver cell injury accompany the fat. Fibrosis is scarring, and cirrhosis is an advanced stage of it. These terms are not synonyms, and distinguishing them affects monitoring and treatment.
What your doctor may check next
Assessment may include liver enzymes, platelets, blood sugar, and blood lipids, alongside underlying conditions, medications, and drinking habits. Normal liver enzymes alone are not enough to rule out significant fibrosis.
A tool such as FIB-4 combines blood test data and age to assess risk. Depending on the result and medical context, your doctor may recommend elastography, a test assessing liver stiffness, or specialist consultation. The number is not a stand-alone diagnosis. Bring previous results and ask what has changed rather than interpreting each line in isolation. The guide to reading blood tests without panic also addresses preparation for that conversation.
Diet and movement remain central to treatment
The European guidelines recommend a Mediterranean-style eating pattern: vegetables, legumes, whole grains, olive oil, and fish, tailored to the individual. They emphasize reducing ultra-processed foods rich in sugar and saturated fat and avoiding sugary drinks. No single food replaces the overall pattern.
For someone with excess weight, gradual, sustained weight loss can reduce liver fat and sometimes improve other measures. The goal should fit your health status, without leading to a severe diet or muscle loss. Someone at a normal weight should not conclude they need to lose weight without an individual assessment.
Physical activity is beneficial even when the scale does not change immediately. Build a routine around your abilities and preferences, combining everyday movement with planned activity. Walking after a meal can be a practical way to start, without attributing treatment of liver disease to it alone.
Alcohol is also part of the assessment. No single quantity can be declared safe for everyone with fatty liver. For advanced fibrosis or cirrhosis, the guidelines recommend complete avoidance; obtain your personal recommendation from your doctor.
The relatively recent approval is not for every finding of liver fat
On August 15, 2025, the FDA granted accelerated approval for semaglutide treatment in adults with noncirrhotic MASH and moderate to advanced fibrosis. According to the FDA approval announcement, the decision was based on improvements in biopsy measures, and continued follow-up is required to confirm benefits in long-term clinical outcomes.
This is a U.S. approval, and it does not establish that the indication is approved or funded in Israel. Nor does it make every person with fatty liver a candidate for this treatment. If you have just received an ultrasound result, the practical step is to arrange an orderly assessment, understand your risk level, and choose changes you can sustain.
This is general news information and is not a substitute for personal advice from a doctor or dietitian.
